Paclitaxel
- Generic Name
- Paclitaxel
- Brand Names
- Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin
- Drug Type
- Small Molecule
- Chemical Formula
- C47H51NO14
- CAS Number
- 33069-62-4
- Unique Ingredient Identifier
- P88XT4IS4D
- Background
Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.
- Indication
Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer
- Associated Therapies
- -
Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)
- Conditions
- Interventions
- First Posted Date
- 2021-10-25
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Mural Oncology, Inc
- Target Recruit Count
- 456
- Registration Number
- NCT05092360
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇪🇸Hospital Clinico Universitario de Valencia, Valencia, Spain
🇨🇳Taichung Veterans General Hospital, Taichung, Taiwan
Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a "Window of Opportunity" Study
- Conditions
- Interventions
- First Posted Date
- 2021-10-05
- Last Posted Date
- 2021-10-05
- Lead Sponsor
- Medical University of Gdansk
- Target Recruit Count
- 126
- Registration Number
- NCT05067530
- Locations
- 🇵🇱
Wielkopolskie Centrum Onkologii im. Marii Skłodowskiej-Curie, Oddział Onkologii Klinicznej i Immunoonkologii z Pododdziałem Dziennym, Poznań, Wielkopolskie, Poland
🇵🇱Dolnośląskie Centrum Onkologii we Wrocławiu, Oddział Onkologii Klinicznej/Chemioterapii, Poradnia Chemioterapii; Leczenie Nowotworów Piersi, Wrocław, Dolnośląskie, Poland
🇵🇱SP ZOZ Opolskie Centrum Onkologii im. Prof. Tadeusza Koszarowskiego, Opole, Opolskie, Poland
Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor
- First Posted Date
- 2021-10-01
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 40
- Registration Number
- NCT05065021
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
A Clinical Study of SI-B001 in Combination With Paclitaxel in the Treatment of Recurrent and Metastatic HNSCC
- Conditions
- Interventions
- First Posted Date
- 2021-09-23
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT05054439
- Locations
- 🇨🇳
The Second Affiliated Hospital of Guilin Medical University, Guilin, Guangxi Zhuang Autonomous Region, China
🇨🇳The Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, Guizhou, China
🇨🇳Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
- Conditions
- Advanced Head and Neck Squamous Cell CarcinomaAdvanced Ovarian Clear Cell AdenocarcinomaChondrosarcomaClinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Pathologic Stage III Cutaneous Melanoma AJCC v8Pathologic Stage IIIA Cutaneous Melanoma AJCC v8Pathologic Stage IIIB Cutaneous Melanoma AJCC v8Pathologic Stage IIIC Cutaneous Melanoma AJCC v8Pathologic Stage IIID Cutaneous Melanoma AJCC v8
- Interventions
- First Posted Date
- 2021-09-10
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 54
- Registration Number
- NCT05039801
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-08-25
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- Baylor Breast Care Center
- Target Recruit Count
- 185
- Registration Number
- NCT05020860
- Locations
- 🇺🇸
Harris Health System - Smith Clinic, Houston, Texas, United States
🇺🇸O'Quinn Medical Tower - McNair Campus - Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States
A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of MK-3475A (Pembrolizumab Formulated With MK-5180) In Advanced Solid Tumors (MK-3475A-C18)
- Conditions
- Interventions
- First Posted Date
- 2021-08-23
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 72
- Registration Number
- NCT05017012
- Locations
- 🇨🇱
James Lind Centro de Investigación del Cáncer ( Site 0102), Temuco, Araucania, Chile
🇨🇱FALP-UIDO ( Site 0101), Santiago, Region M. De Santiago, Chile
🇿🇦Cancercare Rondebosch Oncology-Clinical trials ( Site 0055), Rondebosch, Western Cape, South Africa
Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2021-08-19
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Fundación GECP
- Target Recruit Count
- 71
- Registration Number
- NCT05012254
- Locations
- 🇪🇸
Hospital Provincial de Castellón, Castelló de la Plana, Castellon, Spain
🇪🇸Hospitalario Universitario A Coruña, A Coruña, La Coruña, Spain
🇪🇸Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-08-17
- Last Posted Date
- 2024-04-08
- Lead Sponsor
- AGO Study Group
- Target Recruit Count
- 970
- Registration Number
- NCT05009082
- Locations
- 🇩🇪
Klinikum Neumarkt, Neumarkt, Germany
🇩🇪MVZ Nordhausen, Nordhausen, Germany
🇩🇪Klinikum St. Marien Amberg, Amberg, Germany
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
- Conditions
- Interventions
- First Posted Date
- 2021-08-16
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 604
- Registration Number
- NCT05007106
- Locations
- 🇺🇸
Memorial Sloan Kettering - Bergen ( Site 1025), Montvale, New Jersey, United States
🇺🇸Memorial Sloan Kettering - Monmouth ( Site 1022), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering - Basking Ridge ( Site 1023), Basking Ridge, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.